Copeland Capital Management LLC Has $25.74 Million Stock Holdings in iRadimed Corporation (NASDAQ:IRMD)

Copeland Capital Management LLC lifted its holdings in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 3.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 490,544 shares of the medical equipment provider's stock after buying an additional 14,981 shares during the period. Copeland Capital Management LLC owned approximately 3.86% of iRadimed worth $25,744,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MetLife Investment Management LLC increased its holdings in shares of iRadimed by 11.4% during the fourth quarter. MetLife Investment Management LLC now owns 4,845 shares of the medical equipment provider's stock valued at $266,000 after purchasing an additional 494 shares during the period. Principal Financial Group Inc. raised its holdings in iRadimed by 11.2% during the fourth quarter. Principal Financial Group Inc. now owns 5,440 shares of the medical equipment provider's stock worth $299,000 after purchasing an additional 546 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of iRadimed by 21.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,306 shares of the medical equipment provider's stock worth $897,000 after buying an additional 2,921 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of iRadimed by 8.1% in the fourth quarter. Bank of America Corp DE now owns 25,971 shares of the medical equipment provider's stock valued at $1,428,000 after buying an additional 1,949 shares during the period. Finally, Avantax Advisory Services Inc. acquired a new position in shares of iRadimed in the 4th quarter worth approximately $217,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen raised iRadimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, May 6th.

iRadimed Trading Up 1.2%

IRMD stock traded up $0.72 during mid-day trading on Tuesday, reaching $60.51. 69,996 shares of the stock traded hands, compared to its average volume of 43,806. iRadimed Corporation has a 52-week low of $42.34 and a 52-week high of $63.29. The stock's fifty day moving average is $55.76 and its 200-day moving average is $55.30. The company has a market cap of $769.69 million, a P/E ratio of 39.04 and a beta of 0.92.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Tuesday, May 20th were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend was Tuesday, May 20th. iRadimed's payout ratio is 43.87%.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.